WALTHAM, Mass., Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX),a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in three upcoming investor conferences. The details for the three conferences are:
A live webcast of the Morgan Stanley 16th Annual Global Healthcare Conference fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLLr. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Investor ContactMelissa ForstArgot Partnersmelissa@argotpartners.comTel 212.600.1902
Media ContactDavid Rosen Argot Partners firstname.lastname@example.org Tel 212.600.1902SNDX-G
View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-at-three-upcoming-investor-conferences-300702880.html
SOURCE Syndax Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All